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IMPORTANCE Merkel cell carcinoma (MCC) is an uncommon but highly invasive form of skin
cancer. Themechanisms that cause MCC are yet to be fully determined.
OBJECTIVES To compare the incidence and survival rates of MCC in Queensland, Australia,
known to be a high-risk area, with MCC incidence and survival elsewhere in the world. We
also analyzed incidence trends and differences in survival by key demographic and clinical
characteristics.
DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of population-based
administrative data for MCC collected by the Queensland Cancer Registry and supplemented
with detailed histopathologic data. Deidentified records were obtained of all Queensland
residents diagnosed as having MCC during the period from 1993 to 2010. A subsample of
histopathologic records were reviewed by a senior dermatopathologist to determine the
potential for misclassification. A total of 879 eligible cases of MCCwere included in the study.
MAIN OUTCOMES ANDMEASURES Incidence rates were directly age standardized to the 2000
United States Standard Population. Trends were examined using Joinpoint software with
results expressed in terms of the annual percentage change. The periodmethod was used to
calculate 5-year relative survival, and adjusted hazard ratios were obtained frommultivariate
Poissonmodels.
RESULTS There were 340 cases of MCC diagnosed in Queensland between 2006 and 2010,
corresponding to an incidence rate of 1.6 per 100 000 population. Men (2.5 per 100 000)
had higher incidence than women (0.9 per 100 000), and rates peaked at 20.7 per 100 000
for persons 80 years or older. The overall incidence of MCC increased by an average of 2.6%
per year from 1993 onwards. Relative survival was 41% after 5 years, with significantly better
survival found for those younger than 70 years at diagnosis (56%-60%), those with tumors
on the face or ears (51%), and those with stage I lesions (49%).
CONCLUSIONS AND RELEVANCE Incidence rates for MCC in Queensland are at least double
those of any that have been previously published elsewhere in the world. It is likely that
Queensland’s combination of a predominantly white population, outdoor lifestyle, and
exposure to sunlight has played a role in this unwanted result. Interventions are required to
increase awareness of MCC among clinicians and the public.
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M erkel cell carcinoma (MCC) is a rare andhighly inva-sive formofneuroendocrineskincancer thatwas firstdescribedbyToker1 as trabecular carcinoma in 1972.
Theneoplasms are composedof small, round, blue cells shar-
inghistomorphologicand immunohistochemical featureswith
various neuroectodermally derived cells including cutane-
ous Merkel cells.2,3 It is currently unclear whether MCCs ac-
tually derive from cutaneousMerkel cells or share a common
precursor.2,4,5
Merkel cell carcinomas can be difficult for clinicians to
identify becauseof their nondescript features.6However, just
recently, Jalilian and colleagues7 reported that the 4most fre-
quent clinical features were cherry-red color, shiny surface,
sharp circumscription, and nodular structure. They also out-
linedsignificantdermoscopic features including linear, irregu-
lar, and polymorphous vessels; poorly focused vessels; and
milkypinkareas.7Despite the rather characteristichistopatho-
logic features, immunohistochemical staining is required for
a definitive diagnosis to differentiateMCC froma broad spec-
trum of small, round, blue-cell neoplasms (eg, metastasis of
an oat cell carcinoma of the lung).2,5,8 The tumors typically
showrapidgrowth,meaning thatmanypatientsdevelopmeta-
static disease, and recurrence is common despite surgical re-
moval of the primary lesion.2,8
Merkel cell carcinoma ismost often diagnosed among el-
derlywhitepatientsonsun-exposedbodysitessuchas thehead
and neck.2,5,8 Immunosuppression, which occurs when the
body’s normal immune responses are inhibited due to medi-
cal interventionordisease, is another recognized risk factor,2,5
which is suggestive of a viral cause.8 The discovery of a poly-
omavirus (MCPyV)9 inmost MCC tumors has offered new in-
sights into its pathogenesis,8,10,11 althoughmuch remains un-
known.For example,while there is an established association
between MCC and UV irradiation,8 it is not clear whether UV
irradiation contributes directly to thedevelopment ofMCCor
if it acts in combination with immunosuppression.10
The state of Queensland in northeastern Australia has a
subtropical climate and high levels of UV radiation year-
round combined with a predominantly fair-skinned popula-
tion and an outdoor lifestyle. Queensland consequently has
the highest reported incidence rate of skin cancers world-
wide,particularly invasivemelanoma.12-14Themainaimof the
present studywas tocompare the incidenceofMCC inQueens-
land with that found elsewhere in the world. We also exam-
ined incidence trends and investigated differences in sur-
vival by key demographic and clinical characteristics.
Methods
Data
Approval for this studywas granted by the Griffith University
Human Research Ethics Committee (PBH/34/11/HREC). Be-
cause the study involved a retrospective review of deidenti-
fied records, participant informed consent was not required.
Population-based data on all cases ofMCC (defined as In-
ternational Classification of Diseases for Oncology, Third Edi-
tion (ICD-O-3) codeC44 andmorphology codeM8247-3) diag-
nosed in residents of Queensland between 1993 and 2010,
inclusive, were obtained from the Queensland Cancer Regis-
try. We excluded cases diagnosed prior to 1993 owing to the
possibility of underreporting ofMCC in this period.15 Cases of
MCC were further restricted to those occurring on the skin.
The data available from the Queensland Cancer Registry
included demographic information (sex, age at diagnosis, re-
moteness of residence16), diagnostic details (year and ana-
tomic site), full history of any other cancer diagnoses, and,
where relevant, items relating to mortality (time from diag-
nosis to death and cause of death). Additional clinical infor-
mationwasextracted fromhistopathologyreportswhereavail-
able, including the sizeof the lesion, lymphnode involvement,
recurrence,metastases,and immunohistochemical results. Im-
munosuppression statuswas categorized as “known tobe im-
munosuppressed” for persons who were a transplant recipi-
ent, testedpositive forhumanimmunodeficiencyvirus,orwho
were reported tohave another cause of immune suppression.
Caseswerestagedaccording to thecriteria setoutby theAmeri-
can Joint Committee on Cancer.17
A positive test result for cytokeratin 20 (CK20) was con-
sidered confirmation of a diagnosis of MCC, but other vari-
ants exist that are CK20 negative.4,18 To estimate the poten-
tial for misclassification of cases included in the study, a
subsample of approximately 1 in 10 of the histopathology re-
ports for tumors coded toMCCwhere anegative resultwas re-
turned for CK20orwhereCK20 testingwasnot recordedwere
reviewed by a senior dermatopathologist (H.P.S.).
Statistical Analysis
Annual incidence rates for the period 1993 through 2010 and
average incidence rates for the latest 5 years (2006-2010)were
generated by sex, age group, site, and stage at diagnosis. Es-
timated resident population informationused for the rate de-
nominators was obtained from the Australian Bureau of
Statistics.19 To allow for consistency with other similar
studies,15,20 rates were directly age standardized to the 2000
UnitedStatesStandardPopulation.21 Incidence rate ratioswere
calculated by simple division, with confidence intervals de-
rived using the method specified by Kegler.22
Incidence trendswereanalyzedusing Joinpoint regression
models(softwaredevelopedbytheNationalCancerInstitute,ver-
sion 4.0.4). This approach quantifies the annual percentage
change (APC) andspecifies any significant changes to themag-
nitudeor directionof the trend (knownas a “joinpoint”) based
onMonteCarlopermutationtests.23Amaximumof2 joinpoints
werespecifiedineachmodel,withaminimumof5yearsallowed
between joinpointsorbetweena joinpointandeitherendof the
data series.Two-sided t testswereused todetermine thestatis-
tical significance of the trends (P < .05).
Median survival time, defined as the time fromdiagnosis
to censoringordeath,wascalculatedusing the reverseKaplan-
Meiermethod.24Follow-upwascensoredforsubjectswhowere
alive at the end of the study period and/or at the date of death
for those who died from causes other than MCC for cause-
specific survival analysis.Onecasewasexcluded fromthe sur-
vival analysis owing to diagnosis on the basis of death certifi-
cate only.
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Five-year survival was evaluated using the period
method,25which follows rolling groupsofpatientswithin a re-
cent “at risk” window of time and thus has the advantage of
producingmore up-to-date survival estimates than themore
traditional cohort method. In the current study, persons di-
agnosed as having MCC contributed to the survival calcula-
tions if theirswas aprevalent case at some timebetween Janu-
ary 2006 and December 2010. Estimates for both relative
survival and MCC-specific survival were produced. Relative
survival was calculated by dividing the observed survival
probability for the studygroupby theexpectedsurvivalwithin
theQueenslandpopulation,26matchedby age group, sex, and
year. The Ederer II technique27 was used to compute ex-
pected survival.
Differences in survival were assessed by applying multi-
variatePoissonmodels toexamineexcessmortalityupto5years
after diagnosis,28 with results expressed in terms of adjusted
hazard ratios (HRs). The dependent variable was the number
of deaths,with an offset term for the log of the person-years at
risk. A range of key demographic and clinical variableswas in-
cluded in the initial model to determine which of these char-
acteristicshadindependentprognosticvalue.Variableswereex-
cluded if there was no evidence (P > .25) of their overall effect
on survival (remoteness of residence16 and level of invasion).
Sex, agegroup,bodysite,multipleprimarycancers, stageatdi-
agnosis, and surgicalmarginswere retained in the finalmodel.
If the overall effect for a variable was not statistically signifi-
cant (P ≥ .05), thentherewasdeemedtobenodifference insur-
vival, even if there appeared tobe individual differences in the
adjusted HRs between some of the categories.
All results were presented with corresponding 95% con-
fidence intervals (CIs).
Results
Incidence
A total of 903 cases ofMCCwerediagnosed inQueenslandbe-
tween 1993 and 2010. Of these, 24were excluded because the
lesionoccurredonsitesother than theskin (mainlyonthe lips),
leaving 879 eligible cases in our cohort.
The distributions for some of the main characteristics of
the cohort are listed inTable 1.Menaccounted for around two-
thirds of all cases (68%), with a median age at diagnosis of
75.5 years compared with 78.0 years for women. Half of the
caseswere diagnosed at stage I, while 12% already had lymph
node metastases (stage III), and a further 15% had distant
metastases (stage IV) at the time of diagnosis. Only 1% of
patients in the cohortwere known to be immune suppressed.
More thana third (36%)werediagnosedashaving anotherpri-
mary cancer apart fromMCC, including 10 patients (1%) with
chronic lymphocytic leukemia and 18 patients (2%) with a
lymphoma.
The most common site was the face or ears (35%), al-
though the distribution ofMCC across the body sites differed
by sex (P < .001). In particular, MCCs on the face or ears oc-
curred more frequently for men (38%) than women (29%),
while women were far more likely than men to have an MCC
diagnosed on their lower limbs (26% and 11%, respectively).
Womenalso had ahigher proportion ofMCCs that hadnot yet
penetrated beyond the dermal layers of the skin (31% com-
paredwith23%of theirmale counterparts).Nostatistically sig-
nificant differences by sex were found among MCC patients
by age group at diagnosis, remoteness of residence,16 pres-
ence of any multiple primary cancers (including second pri-
mary MCCs), stage at diagnosis, surgical margins, or immu-
nosuppression status.
The average annual age-standardized incidence rate of
MCCs in Queensland between 2006 and 2010 was 1.6 per
100 000 population (95% CI, 1.5-1.8; see the eTable in the
Supplement). Incidencewasalmost 3 timeshigher formen (2.5
per 100 000) than for women (0.9 per 100 000). Rates in-
creased rapidly by age, peaking at 20.7 per 100 000 for per-
sons 80 years or older.
Incidence rate trends forMCC inQueensland increasedby
an average of 2.6%per year (95%CI, 1.1%-4.2%) between 1993
and 2010, equating to a total rise of 54% over that time inter-
val (Table 2 and Figure 1). Significant and ongoing annual in-
creaseswere foundformen(+2.5%peryear),people in theolder
age groups (70-79 years, +2.3%; 80 years or older, +3.7%), and
tumors that occurred on the head (+3.1%). Significant in-
creaseswere also observed for tumors thatwere either stage I
(+3.6%) or stage II or higher (+2.9%).
Survival
Therewere281deathsduetoMCCwithin thestudygroup(32%)
between 1993 and2010.A further 82people in the cohort (9%)
died from other types of cancers; 213 deaths (24%)were from
noncancer causes; and the remaining 303 persons (34%)were
still aliveat theendof 2010.Of theother cancer-relateddeaths,
themain causeswere other types of skin cancer and lung can-
cer (14 deaths each).
Themedian follow-up time for cases that were prevalent
between2006and2010was 2.8 years (interquartile range, 1.2-
6.1 years). Cause-specific survival was 88% (95% CI, 84%-
91%) after 1 year and66% (95%CI, 60%-71%) after 5 years. The
correspondingestimates for 1- and5-year relative survivalwere
77% (95% CI, 71%-81%) and 41% (95% CI, 34%-48%), respec-
tively.
Afteradjustment forconfoundingvariables, significantdif-
ferences in survival remained for age group, site, and stage at
diagnosis (Table 3 andFigure 2). Specifically, persons80years
orolderwere3 timesmore likely todie fromMCCwithin5years
of diagnosis compared with those aged 60 to 69 years (ad-
justedHR, 3.0; 95%CI, 1.8-5.1). Personswith anMCConeither
the trunk (adjustedHR, 2.2; 95%CI, 1.2-4.1) or lower limbs (ad-
justed HR, 1.8; 95% CI, 1.1-3.0) had around double the risk of
MCC-relatedmortality comparedwithMCCon the faceor ears;
however, therewasno significantdifference for lesionson the
scalp or neck and upper limbs or shoulders in relation to the
faceor ears. The riskofMCC-relatedmortalitywasalso around
double for either stage II (adjusted HR, 1.8; 95% CI, 1.1-3.2) or
stage IV tumors (adjusted HR, 2.3; 95% CI, 1.2-4.4) compared
with stage I.No significant survival differenceswere found for
sex, remoteness of residence, level of invasion, surgical mar-
gins, or the presence of multiple primary cancers.
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Discussion
Toour knowledge, this report provides the first descriptionof
the epidemiology forMCC in the state ofQueensland, Austra-
lia. Several recent population-based studies have been pub-
lished on the incidence of MCC.15,20,29-32 Rates in these other
studies vary from0.2per 100 000 inDenmark29 andFinland32
to 0.8 per 100 000 in Western Australia.15 Our results there-
fore reveal that the incidence rate ofMCC in Queensland is at
least double that previously reported anywhere else in the
world.
Queensland has a predominantlywhite population living
in an area with high levels of ambient UV radiation through-
out the year.33 The higher incidence reported here compared
with other countries and/or regions therefore appears to sup-
port a link between exposure to UV radiation andMCC and is
consistent with the findings of Agelli and Clegg,34 who noted
Table 1. Characteristics of Persons Diagnosed as HavingMerkel Cell Carcinoma
by Sex, Queensland, Australia, 1993-2010
Characteristic
Cases, No. (%) χ2 (df) P Value
Men Women Persons
Total 602 (100.0) 277 (100.0) 879 (100.0)
Age at diagnosis, y
0-39 6 (1.0) 1 (0.4) 7 (0.8)
6.16 (4) .19
40-59 59 (9.8) 18 (6.5) 77 (8.8)
60-69 118 (19.6) 47 (17.0) 165 (18.8)
70-79 204 (33.9) 94 (33.9) 298 (33.9)
≥80 215 (35.7) 117 (42.2) 332 (37.8)
Body site
Face/ears 228 (37.9) 79 (28.5) 307 (35.0)
41.35 (5) <.001
Scalp/neck 77 (12.8) 24 (8.7) 101 (11.5)
Trunk 47 (7.8) 25 (9.0) 72 (8.2)
Upper limbs/shoulders 75 (12.5) 44 (15.9) 119 (13.5)
Lower limbs 66 (11.0) 72 (26.0) 138 (15.7)
Not specified 109 (18.1) 33 (11.9) 142 (16.2)
Remoteness of residencea
Major city 337 (56.0) 157 (56.7) 494 (56.2)
5.60 (4) .23
Inner regional 146 (24.3) 58 (20.9) 204 (23.2)
Outer regional 89 (14.8) 40 (14.4) 129 (14.7)
Remote/very remote 28 (4.7) 18 (6.5) 46 (5.2)
Not stated 2 (0.3) 4 (1.4) 6 (0.7)
Multiple primary cancers (all types)
No 370 (61.5) 192 (69.3) 562 (63.9)
5.57 (2) .06Yes, previous years 155 (25.7) 53 (19.1) 208 (23.7)
Yes, same/subsequent years 77 (12.8) 32 (11.6) 109 (12.4)
Stage at diagnosisb
I 295 (49.0) 143 (51.6) 438 (49.8)
4.42 (4) .35
II 55 (9.1) 34 (12.3) 89 (10.1)
III 71 (11.8) 31 (11.2) 102 (11.6)
IV 101 (16.8) 35 (12.6) 136 (15.5)
Unknown 80 (13.3) 34 (12.3) 114 (13.0)
Level of invasionc
Dermis 141 (23.4) 87 (31.4) 228 (25.9)
6.31 (2) .04Dermis/subcutaneous 243 (40.4) 101 (36.5) 344 (39.1)
Not stated 218 (36.2) 89 (32.1) 307 (34.9)
Surgical margins
Satisfactory (clear) 278 (46.2) 143 (51.6) 421 (47.9)
2.28 (2) .32Unsatisfactory (not clear) 123 (20.4) 52 (18.8) 175 (19.9)
Not stated 201 (33.4) 82 (29.6) 283 (32.2)
Immune statusd
Known to be immune suppressed 8 (1.3) 4 (1.4) 12 (1.4)
0.02 (1) .89
Not known to be immune suppressed 594 (98.7) 273 (98.6) 867 (98.6)
Abbreviations: df, degrees of
freedom; HIV, human
immunodeficiency virus.
a Remoteness of residence defined by
the Australian Standard
Geographical Classification
Remoteness Areas.16
b Stage at diagnosis defined
according to the criteria set out by
the American Joint Committee on
Cancer.17
c Dermis category may include
epidermal involvement;
dermis/subcutaneous category
includes cases where the tumor
extended beyond the dermal layer.
d Immune status was categorized as
suppressed for a person known to
be a transplant recipient, HIV
positive, or reported to have
another cause of immune
suppression.
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a correlation between the UV index and rates of MCC in the
United States. In addition, most cases of MCC in Queensland
were found on sun-exposed sites such as the face and ears,
scalp and neck, and upper limbs and shoulders, whereas in a
less sunnycountry suchasSweden, a relatively largerpercent-
age of MCCs were observed on the trunk.30 Similar to Gir-
schikandcolleagues15working inWesternAustralia,whichalso
has a high UV index, we found that MCCs occurred more fre-
quently formen than inwomen. This contrastswithwhat has
been reported in several places in Europe.29-32
Average age at diagnosis in other studies ranged from 75
to 78 years, consistent with the median of 76 years of age in
theQueensland cohort. However, a higher proportion ofMCC
tumors inQueenslandwere found to have distantmetastases
at diagnosis (15%) as opposed to MCC tumors studied else-
where (4%-8%).15,20,29,31,32
Therewasanannual increaseof8%inthe incidenceofMCC
in the United States between 1986 and 2001,35 while rates
doubled in the Netherlands between 1993 and 2007.31 Al-
though the magnitude of the increase in both of these coun-
tries has been considerably greater than that observed in
Queensland, their incidence rates still remainmuch lower.The
incidence of MCC has stayed fairly stable in Nordic countries
since the mid-1990s.32 At least part of the rapid increase in
incidence rates in the United States during the last 2 to 3
decades has been attributed to advances in diagnostic tech-
niques, such as immunohistochemical analysis, along with
greater awareness on the part of medical practitioners.4,20
This means that a larger proportion of MCC cases are now
correctly identified. Changes in the proportion of the popu-
lation who are immunosuppressed could also have
contributed.31 It is unknown to what extent these factors
might have influenced incidence rate trends in Australia or
why there has been no corresponding change in incidence
rates of MCC in countries such as Finland, Sweden, Den-
mark, Iceland, and Norway.32
Althoughthe incidence rateofMCCisabout40times lower
than thatof invasivemelanoma inQueensland,36 these 2 types
of skin cancer share some epidemiologic characteristics. For
example, they aremore commonamongmenand the elderly.
The incidenceof both is continuing to increase sharply among
older people,while rateshave stabilized among thosewhoare
younger.13 If theroleofUVradiation in thedevelopmentofMCC
is found to be similar to that inmelanomadevelopment, then
thisstabilizingof ratesamongyoungerpeoplemayprovidesup-
port for the effectiveness of prevention campaigns.37
Ananalysisofdata fromFinlandreportedanestimatesimi-
lar to ours for 5-year relative survival amongmen (36%) but a
muchhigher rate forwomen (69%).32 Lemos et al17 calculated
a 5-year relative survival rate of 54% for a large series of pa-
tients with MCC from the United States, whereas other stud-
ies have estimated relative and cause-specific survival rates
of 62% and 64% after 5 years in the Netherlands31 and West-
ernAustralia,15 respectively.While these results are similar to
our estimate for cause-specific survival, they are substan-
tially higher than the relative survival rate in Queensland.
In most instances, relative survival closely resembles
cause-specific survival estimatesbecause thesemetrics arede-
signed to measure the same outcome of net survival. An ex-
ception iswhen the underlyingmortality in the cohort is sub-
stantially different from that of the general population after
accounting for thediseaseof interest.38This couldexplainwhy
therewasa largedisparitybetweenthe2measures inourstudy.
Even so, it is still not clear why our estimate of relative sur-
vival was substantially lower than some of the other pub-
lishedresults, althoughthehigherproportionofcaseswithme-
tastases at diagnosis in the Queensland cohort may have
contributed to these differences to some extent.
Several prognostic factors for MCCs have been identified
by other researchers, including sex, site, immune suppres-
sion, histopathologic type, growth pattern, and most impor-
tantly, the extent of disease at presentation (variously char-
Table 2. Annual Percentage Change (APC)a in the Incidence Ratesb ofMerkel Cell Carcinoma
By Selected Characteristics, Queensland, Australia, 1993-2010
Characteristic Cases, No. APC (95% CI) P Value
Total 879 2.6 (1.1 to 4.1) .002
Sex
Men 602 2.5 (0.9 to 4.1) .004
Women 277 2.1 (−0.7 to 5.1) .13
Age at diagnosis, y
0-59 84 −1.4 (−5.8 to 3.2) .52
60-69 165 2.0 (−1.1 to 5.1) .20
70-79 298 2.3 (0.1 to 4.6) .04
≥80 332 3.7 (1.0 to 6.4) .01
Body sitec
Head 408 3.1 (1.1 to 5.2) .01
Other 329 1.3 (−1.1 to 3.8) .26
Not specified 142 2.2 (−1.5 to 6.1) .23
Stage at diagnosisd
Stage I 438 3.6 (1.1 to 6.2) .01
Stage ≥II 327 2.9 (0.2 to 5.6) .04
Unknown 114 −2.9 (−6.2 to 0.5) .09
Abbreviation: APC, annual
percentage change.
a Calculated using Joinpoint
regression software.
bRates were directly age
standardized to the 2000United
States Standard Population.21
c Head includes the face, ears, scalp,
and neck; other body site includes
the trunk, upper limbs, shoulders,
and lower limbs.
d Stage at diagnosis defined
according to the criteria set out by
the American Joint Committee on
Cancer.17
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acterized by stage, tumor size or depth, and lymphovascular
invasion).5,15,20,39 The influence of MCPyV on survival is
controversial,10,11 but wewere not able tomeasure this in the
current study. We found significant differences in the risk of
mortality by age, body site, and stage at diagnosis after mul-
tivariateanalysis.Onenotabledifferencewas thatMCCson the
head and neck have been previously associatedwith a poorer
prognosis,5which is theopposite ofwhat occurred inQueens-
land. The reasons for this are not evident.
The prognosis for people diagnosed with MCC is clearly
worse than that for thosewithmelanoma: 5-year relative sur-
vival formelanomawas93%inQueensland for theperiod2006
through 2010,36 in contrast to 41% forMCC. It seems unlikely
that this difference is due tomelanomas beingdiagnosed ear-
lier than MCCs: Girschik et al15 reported significantly worse
stage-specific survival forMCC comparedwithmelanoma for
localized and regional disease but not for distantmetastases.
Another possible explanation is that differences exist in the
general health of those diagnosed as having MCC vs mela-
noma.More thanhalfof thedeathswithin theMCCcohortwere
due toother causes. It is therefore feasible that serious comor-
bidities were also common among those whose deaths were
attributed toMCC,whichwould thus have had a negative im-
pact in addition to that of theMCC tumor on patient survival.
MostpreviousstudiesonMCChave involvedsmall samples
of fewer than 200 patients. Therefore, a main strength of our
work is the larger size of the cohort. The inclusion of all cases
diagnosed in Queensland means that the study was not sub-
ject to some of the selection biases that can result from a hos-
pital-basedseriesofpatients.Another advantage is the supple-
mentation of standard registry data items with information
from histopathology reports.
Only 1% of patients included in our data were docu-
mented as being immunosuppressed, comparedwith 6% in a
population-based MCC cohort from Western Australia.15 In-
formation about immunosuppression status is not routinely
reported inQueensland, so our resultwas probably anunder-
estimateof the trueproportion.Unfortunately, the small num-
ber of immunosuppressed cases alsomeant that wewere un-
able to assess survival for this subgroup.
While every effort was made to verify legitimate MCC
cases,wedidnothaveaccess tostoredbiologicalmaterial (such
Figure 1. Incidence Rate Trends forMerkel Cell Carcinoma, Queensland, Australia, 1993-2010
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as specimens and tissue blocks) to assist with this process.
While immunohistochemical results other than CK2040 were
available to confirmthediagnosis in approximately80%of the
audited histopathology records, the audit revealed that up to
5%of the patients included in this studymayhave been over-
diagnosed.However, this is a conservativelyhighestimateand
is considered acceptable when taking into account the spe-
cific histopathologic diagnostic challengeswhendealingwith
small, round,blue-cell tumorsof the skin.Conversely, it is also
possible that some cases of MCC were inadvertently ex-
Table 3. 5-Year Relative Survivala and Adjusted HRs forMerkel Cell Carcinoma by Selected Characteristics, Queensland, Australia, 2006-2010
Characteristic Cases, No.b
5-Year Relative
Survival,
% (95% CI)a
Adjusted HR
(95% CI) P Value Categorical χ2 (df) Categorical P Value
Total 489 41.3 (34.4-48.4) NA NA NA NA
Sex
Men 338 38.2 (30.0-46.8) 1 [Reference] NA
1.59 (1) .21
Women 151 48.1 (35.5-60.4) 0.77 (0.51-1.16) .21
Age group at diagnosis, y
0-59 47 56.5 (35.8-73.1) 0.75 (0.36-1.58) .45
29.03 (3) <.001
60-69 95 59.9 (43.5-73.6) 1 [Reference] NA
70-79 165 43.2 (32.0-54.4) 1.42 (0.83-2.44) .20
≥80 182 24.6 (14.0-38.3) 3.00 (1.76-5.10) <.001
Body site
Face/ears 186 51.3 (38.5-64.0) 1 [Reference] NA
12.00 (5) .04
Scalp/neck 47 45.2 (19.9-73.2) 1.02 (0.52-2.00) .96
Trunk 41 24.8 (10.2-43.6) 2.19 (1.16-4.13) .02
Upper limbs/shoulders 63 38.1 (20.4-57.5) 1.40 (0.77-2.53) .27
Lower limbs 76 33.3 (20.0-48.3) 1.81 (1.08-3.00) .02
Not specified 76 33.2 (17.9-50.3) 0.90 (0.43-1.88) .78
Remoteness of residencec,d
Major city 273 38.6 (29.7-48.1) NAc NAc
NAc NAcInner regional 119 51.3 (35.5-67.0) NAc NAc
Other/unknown 97 36.8 (23.6-50.9) NAc NAc
Multiple primary cancers (all types)
No 316 46.2 (37.1-55.2) 1 [Reference] NA
4.06 (2) .13Yes, previous years 122 29.8 (17.4-44.3) 1.50 (1.01-2.23) .045
Yes, same/subsequent years 51 37.0 (20.0-55.8) 1.22 (0.69-2.17) .50
Stage at diagnosise
I 266 48.8 (38.8-58.7) 1 [Reference]
9.91 (4) .04
II 53 26.2 (8.9-50.1) 1.83 (1.06-3.15) .03
III 53 41.4 (21.7-63.1) 1.55 (0.87-2.74) .14
IV 70 25.4 (13.4-39.8) 2.29 (1.21-4.36) .01
Unknown 47 43.1 (19.5-68.7) 1.01 (0.50-2.06) .98
Level of invasionc,f
Dermis 141 45.5 (31.5-59.9) NAc NAc
NAc NAcSubcutaneous 204 41.9 (31.7-52.5) NAc NAc
Not stated 144 37.2 (25.3-49.7) NAc NAc
Surgical margins
Satisfactory (clear) 272 47.5 (37.7-57.3) 1 [Reference]
3.77 (2) .15Unsatisfactory (not clear) 86 39.9 (24.1-57.1) 1.29 (0.81-2.04) .28
Not stated 131 30.1 (18.9-42.5) 1.68 (0.96-2.94) .07
Abbreviations: df, degrees of freedom; HR, hazard ratio; NA, not applicable;
a Survival calculated using the periodmethod for persons whowere at risk of
mortality due toMerkel cell carcinoma January 1, 2006, through December 31,
2010.
b The number of persons whowere eligible to contribute to the 5-year relative
survival calculations.
c Remoteness of residence and level of invasion were excluded from the final
multivariate Poissonmodel for calculating the HRs because the overall effect
for these variables was P > .25.
dRemoteness of residence defined by the Australian Standard Geographical
Classification Remoteness Areas.16
e Stage at diagnosis defined according to the criteria set out by the American
Joint Committee on Cancer.17
f Dermis category may include epidermal involvement; dermis/subcutaneous
category includes cases where the tumor extended beyond the dermal layer.
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cludedowing to incorrect classificationas another typeof can-
cer, but it was not possible to confirm this.
Conclusions
Our results establish that the incidence rate of MCC is much
higher inQueenslandthananywhereelse in theworld.Thecen-
tral factorbehind thisundesirable statistic appears tobeahigh
levelofexposure toUVradiationbyamainly fair-skinnedpopu-
lation. While the greater attention placed on melanoma may
bewarranted given its higher incidence, people diagnosed as
havingMCChavegreatly reducedsurvivalexpectations. In light
of these findings, it is imperative that clinical practice guide-
lines for the diagnosis and management of MCC be devel-
oped and implemented within Australia as soon as possible,7
similar to those that alreadyexist for other countries.41,42 Pub-
lic awareness campaigns are also required to alert people that
melanoma is not the only lethal form of skin cancer. In par-
ticular, timely medical evaluation should be encouraged for
the rapid appearance of a new lesion, with emphasis on the
importance of people becoming familiar with what is normal
for their own skin. It is hoped that these stepswill lead to bet-
ter outcomes for patients with MCC.
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